ASK PI - HER2 Breast Cancer Clinical Progress

• China Time: 9 am, Sat, Dec. 4th, 2021
• US EST: 8 pm, Fri, Dec. 3rd, 2021
• US PST: 5 pm, Fri, Dec. 3rd, 2021

• Prof. Qiang Liu, Sun Yat-sen Memorial Hospital
• Prof. Sara A. Hurvitz, University of California Los Angeles (UCLA)

• Prof. Sara A. Hurvitz, University of California Los Angeles (UCLA)

• Prof. William J. Gradishar, Northwestern University

• Prof. Qiang Liu, Sun Yat-sen Memorial Hospital
• Prof. Sara A. Hurvitz, University of California Los Angeles (UCLA)
• Prof. William J. Gradishar, Northwestern University
• Prof. Shusen Wang, Sun Yat-Sen University Cancer Center
• Prof. Tao Wang, The Fifth Medical Center of PLA General Hospital
• Prof. Ying Fan, Cancer Hospital Chinese Academy of Medical Sciences
• Prof.Xu Liang, Associate Chief Physician

• Prof. Qiang Liu, Sun Yat-sen Memorial Hospital

Dr. Liu graduated from Xiangya School of Medicine in 1996, after then Dr. Liu got PHD from National University of Singapore in 2004. During 2008-2011 Dr.Liu worked as a instructor in Dana Farber Cancer Center. Now Dr. Liu is Professor and Executive vice-president of Yat-sen Breast Tumor Hospital. Besides, Dr. Liu has lots of academic role in many insititution, such as one of panel members of Breast Cancer in Young Women (BCY5) International Consensus, ESO-ESMO, and one member of Asian Breast Cancer Collaboration Group. Dr. Liu have many contribution in CSCO (Chinese Society of Clinical Oncology) and CACA (Chinese Anti-Cancer Association). Dr. Liu has been engaged in clinical and scientific research work of breast cancer surgery for a long time, and has in-depth research on early diagnosis and individualized treatment of breast cancer. He is good at breast cancer surgery and individualized precise treatment, as well as the differential diagnosis of benign breast disease and breast cancer. He has hosted a number of NSFC projects, including key projects, general projects and national Key Basic Research Program 973 projects, to study the mechanism of breast cancer drug resistance to endocrine therapy and chemotherapy. As the first author or corresponding author, Dr. Liu has published many SCI papers in Cell, Cancer Cell and Nature Communications, participated in the editing of many English Cancer academic monographs, and delivered a speech in international Cancer academic conferences for many times.

• Prof. Sara A. Hurvitz, University of California Los Angeles (UCLA)

Sara A Hurvitz, MD, is Professor of Medicine at the University of California, Los Angeles (UCLA); co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of Breast Oncology. Dr. Hurvitz earned her MD from the University of Southern California. She served internship/residency at UCLA, was Chief Resident of internal medicine and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology.   

Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA. 

• Prof. William J. Gradishar, Northwestern University

William J. Gradishar, MD, FACP, is a Betsy Bramsen Professor of Breast Oncology and professor of medicine and deputy chief in the Division of Hematology/Oncology at the Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois. He is also director of the Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials. He completed his residency at the University of Illinois College of Medicine in Chicago.

Dr. Gradishar is a fellow of both the American Society of Clinical Oncology (ASCO) and the American College of Physicians, as well as a member of the American Association for Cancer Research and the American Federation for Medical Research. He has held numerous leadership positions at ASCO and has been a member of numerous study sections for funding agencies, including the Department of Defense, the National Institutes of Health, the Susan G. Komen Foundation, and the American Cancer Society. He has served as a consultant to the US Food and Drug Administration’s Oncology Drug Advisory Committee, and he is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group.

Dr. Gradishar is a member of the editorial boards of the Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Oncology, and Oncology. He is the currently the editor-in-chief of NEJM Journal Watch: Oncology and Hematology.

Dr. Wang got his PhD from Sun Yat-sen University in 2004. He went to Memorial Sloan-kettering Cancer Center for further education in 2010. Dr. Wang started his career in Sun Yat-sen University Cancer Center after graduation. Now he is Chief physician of Sun Yat-sen University Cancer Center. Besides, Dr. Wang has many academic role in lots of institutions, such as chairman of Chest Cancer Prevention and Control Institute of Guangdong Province Professional Committee of Breast Cancer, vice Chairman of Mammary Gland at the Chinese Academy of Research Hospital Professional Committee, member of CACA (Chinese Anti-Cancer Association), vice Chairman of Guangdong Anti-cancer Association Professional Committee of Breast Cancer. Dr. Wang contributed to many breast cancer guideline and consensus development in China.

Dr. Wang has been working on clinical and scientific research work of breast cancer over 20 years. He has rich experience in breast cancer treatment and prevention. Dr. Wang focused on breast cancer medical therapy, especially refractory breast cancer. Dr. Wang initiated 5 national multi-center clinical studies and 2 phase I clinical studies of new drugs. He also participated in 8 international multi-center clinical studies and 16 domestic multi-center clinical studies. Besides, Dr. Wang and his team researched on related factors in tumor signal transduction pathway in the genesis, development and prognosis of tumor. Dr. Wang has many academic publication in Signal Transduction and Targeted Therapy, MOLECULAR CANCER, CANCER COMMUNICATIONS, JAMA,JNCI et.

• Prof. Tao Wang, The Fifth Medical Center of PLA General Hospital

Head of the Fourth Ward of Department of Medical Oncology, Department of Medical Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Vice Chairman of Specialized Committee of Nervous System Oncology, Member of Expert Committee of Breast Diseases, CSCO, Vice Chairman of Qing Committee of Beijing Breast Disease Prevention and Control Association, Standing Committee Member of Specialized Committee of Breast Diseases, Chinese Anti-Cancer Association, has been engaged in the clinical work of diagnosis and treatment of breast tumors for more than 20 years and has been a visiting scholar of MayoClinic Breast Center in the United States. Undertook five projects including the National Natural Science Foundation of China. He signed more than 50 articles and edited and participated in the compilation of 10 monographs. He is good at comprehensive treatment of breast cancer and clinical research of new drugs and new regimens.

• Prof. Ying Fan, Cancer Hospital Chinese Academy of Medical Sciences

Dr. Fan graduated from Peking Union Medical College in 2003 and worked in Cancer Hospital, CAMS from then on. She was a visiting scholar in Royal Marsden Hospital & Institute of Cancer Research UK from 2008-2009. She also worked as an external expert in CDE (Chinese Drug Evaluation) for 3 months. She specializes in breast Cancer, translational research and clinical trials. She was in charge of several researches such as National Natural Science Foundation for young scientist. She is also sub-investigator for many clinical trials. There are more than 30 publications and she was member for at least four national prizes including first prize from CACA (Chinese Anti-Cancer Association). Currently she is the vice chairman of several Committees including CMEA (China Medicine Education Association), Youth Committee of Beijing Breast Disease Society and of youth committee of clinical trials for anti-cancer drugs, CACA and lots of other committee members.

Dr. Fan speaks English well. She was consecutive and simultaneous interpreter for many international meetings held in China early from 2004, e.g. NCCN；CSCO；CCMO; Best of ASCO; Asia-Pacific Oncology Conference etc. She was also invited speaker in EBCC-SINO joint symposium and CSCO-ASCO joint symposium in 2016.

• Prof.Xu Liang, Associate Chief Physician

Youth Committee Member, Breast group, China Anti-Cancer AssociationMember of Professional Committee of Clinical Oncology, China medical Women’s Association

Youth Committee Member, Professional Committee of Internal Medicine, Beijing Breast Society

Liang graduated from the Peking University People's Hospital in 2005, then she joined the Department of Breast Medicine, School of Clinical Oncology, Peking University until now, and had studied at Tokyo Cancer Center, Japan, in 2008. As a visiting Professor at the Institut Curie, France from 2016 to 2018. She has been engaged in the diagnosis and treatment of advanced breast cancer for a long time. The main research direction and focus are standardized treatment and individualized treatment of advanced breast cancer. As the investigator and sub-investigator, She has participated multiple international and domestic multicenter clinical trials focusing on advanced breast cancer and published more than ten papers in SCI and core journals in China.

Event Venue

Online